Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582952 | 0.82 | CDK2 (0.44) | USP30PARP1GLSBTKCDK2 | |
| SCHEMBL20582953 | 0.82 | CDK2 (0.44) | USP30PARP1GLSBTKCDK2 | |
| SCHEMBL31006833 | 0.81 | CCNK (0.47) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL1514139 | 0.79 | CCNA2 (0.46) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL1120230 | 0.79 | CYP3A4 (0.52) | USP30PIK3CDGPR119 | |
| SCHEMBL889083 | 0.78 | USP30 (0.50) | ALDH1A1MAPTUSP30PIK3CDBTK | |
| SCHEMBL30089181 | 0.78 | GPR119 (0.52) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL23897534 | 0.77 | CDK2 (0.68) | CDK2CDK7CDK9 | |
| SCHEMBL23897532 | 0.77 | CDK9 (0.60) | CDK2CDK7CDK9 | |
| SCHEMBL4354913 | 0.77 | PIK3CD (0.49) | MEN1ALDH1A1MAPTKMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019515-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | CDK1, CDK13, CDK3 | MEN1 509/4885ALDH1A1 4825/4885MAPT 455/4885 |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | MEN1 509/4885ALDH1A1 4825/4885MAPT 455/4885 |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | MEN1 509/4885ALDH1A1 4825/4885MAPT 455/4885 |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | MEN1 509/4885ALDH1A1 4825/4885MAPT 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.